Interleukin-16 inhibits immunoglobulin E production by B lymphocytes

International Archives of Allergy and Immunology

Volumn 143, Issue 2, 2007, Pages 109-118

  Trudelle, Annick ^a,b   El Bassam, Souad ^a,b   Pinsonneault, Stéphane ^a,b   Mazer, Bruce ^c   Laberge, Sophie ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Atopy; Immunoglobulin E; Interleukin 16

Indexed keywords

ANTIBODY; CD14 ANTIGEN; CD40 ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 16; MESSENGER RNA; RECOMBINANT INTERLEUKIN 4; UNCLASSIFIED DRUG;

ARTICLE; ATOPY; B LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-13; INTERLEUKIN-16; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34248387593     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098659     Document Type: Article

References (48)

1. Oettgen HC, Geha RS: IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 2001;107:429-440.
2. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, Levitt RC: Genetic susceptibility to asthma - bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med 1995;333:894-900.
3. Busse W, Corren J, Lanier BQ, et al: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-190.
4. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108:E36.
5. Corren J, Casale T, Deniz Y, Ashby M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111:87-90.
6. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J: The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088-1094.
7. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della CG: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-261.
8. Oshiba A, Hamelmann E, Takeda K, Bradley KL, Loader JE, Larsen GL, Gelfand EW: Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice. J Clin Invest 1996;97:1398-1408.
9. Coyle AJ, Wagner K, Bertrand C, Tsuyuki S, Bews J, Heusser C: Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a nonanaphylactogenic anti-IgE antibody. J Exp Med 1996;183:1303-1310.
10. Hamelmann E, Vella AT, Oshiba A, Kappler JW, Marrack P, Gelfand EW: Allergic airway sensitization induces T cell activation but not airway hyperresponsiveness in B cell-deficient mice. Proc Natl Acad Sci USA 1997;94:1350-1355.
11. MacLean JA, Sauty A, Luster AD, Drazen JM, De Sanctis GT: Antigen-induced airway hyperresponsiveness, pulmonary eosinophilia, and chemokine expression in B cell-deficient mice. Am J Respir Cell Mol Biol 1999;20:379-387.
12. Bacharier LB, Geha RS: Molecular mechanisms of IgE regulation. J Allergy Clin Immunol 2000;105:S547-S558.
13. Cruikshank W, Center DM: Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol 1982;128:2569-2574.
14. Center DM, Cruikshank W: Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes from mitogen-stimulated mononuclear cells. J Immunol 1982;128:2563-2568.
15. Parada NA, Center DM, Kornfeld H, Rodriguez WL, Cook J, Vallen M, Cruikshank WW: Synergistic activation of CD4+ T cells by IL-16 and IL-2. J Immunol 1998;160:2115-2120.
16. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H: Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994;91:5109-5113.
17. Cruikshank WW, Berman JS, Theodore AC, Bernardo J, Center DM: Lymphokine activation of T4+ T lymphocytes and monocytes. J Immunol 1987;138:3817-3823.
18. Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF, Center DM: IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 1996;157:5240-5248.
19. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW: CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 1996;157:1958-1964.
20. Bellini A, Yoshimura H, Vittori E, Marini M, Mattoli S: Bronchial epithelial cells of patients with asthma release chemoattractant factors for T lymphocytes. J Allergy Clin Immunol 1993;92:412-424.
21. Cruikshank WW, Long A, Tarpy RE, Kornfeld H, Carroll MP, Teran L, Holgate ST, Center DM: Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 α (MIP1α) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995;13:738-747.
22. Laberge S, Durham SR, Ghaffar O, Rak S, Center DM, Jacobson M, Hamid Q: Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment. J Allergy Clin Immunol 1997;100:569-574.
23. Laberge S, Ernst P, Ghaffar O, Cruikshank WW, Kornfeld H, Center DM, Hamid Q: Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 1997;17:193-202.
24. Laberge S, Ghaffar O, Boguniewicz M, Center DM, Leung DY, Hamid Q: Association of increased CD4+ T-cell infiltration with increased IL-16 gene expression in atopic dermatitis. J Allergy Clin Immunol 1998;102:645-650.
25. Laberge S, Pinsonneault S, Varga EM, Till SJ, Nouri-Aria K, Jacobson M, Cruikshank WW, Center DM, Hamid Q, Durham SR: Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. J Allergy Clin Immunol 2000;106:293-301.
26. Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, Center DM, Fabel H: Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000;162:105-111.
27. Pullerits T, Linden A, Malmhall C, Lotvall J: Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis. Allergy 2001;56:871-877.
28. Chupp GL, Wright EA, Wu D, Vallen-Mashikian M, Cruikshank WW, Center DM, Kornfeld H, Berman JS: Tissue and T cell distribution of precursor and mature IL-16. J Immunol 1998;161:3114-3119.
29. Kramer MF, Mack B, Rasp G: Immunohistological expression of interleukin 16 in human tonsils. Arch Otolaryngol Head Neck Surg 2001;127:1120-1125.
30. Wood N, Bourque K, Donaldson DD, Collins M, Vercelli D, Goldman SJ, Kasaian MT: IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol 2004;231:133-145.
31. El Bassam S, Pinsonneault S, Kornfeld H, Ren F, Menezes J, Laberge S: Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells. Immunology 2006;117:89-96.
32. Klimiuk PA, Goronzy JJ, Weyand CM: IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 1999;162:4293-4299.
33. Keates AC, Castagliuolo I, Cruickshank WW, Qiu B, Arseneau KO, Brazer W, Kelly CP: Interleukin 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology 2000;119:972-982.
34. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M: Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 2001;28:12-21.
35. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW: Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002;11:181-185.
36. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H: Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998;37:1334-1337.
37. Reich K, Hugo S, Middel P, Blaschke V, Heine A, Gutgesell C, Williams R, Neumann C: Evidence for a role of Langerhans cell-derived IL-16 in atopic dermatitis. J Allergy Clin Immunol 2002;109:681-687.
38. Cruikshank WW, Greenstein JL, Theodore AC, Center DM: Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J Immunol 1991;146:2928-2934.
39. Kaser A, Dunzendorfer S, Offner FA, Ryan T, Schwabegger A, Cruikshank WW, Wiedermann CJ, Tilg H: A role for IL-16 in the cross-talk between dendritic cells and T cells. J Immunol 1999;163:3232-3238.
40. Della Bella S, Nicola S, Timofeeva I, Villa ML, Santoro A, Berardi AC: Are interleukin-16 and thrombopoietin new tools for the in vitro generation of dendritic cells? Blood 2004;104:4020-4028.
41. Pinsonneault S, El Bassam S, Mazer B, Cruikshank WW, Laberge S: IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. J Allergy Clin Immunol 2001;107:477-482.
42. Hessel EM, Cruikshank WW, Van Ark I, de Bie JJ, Van Esch B, Hofman G, Nijkamp FP, Center DM, Van Oosterhout AJ: Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma. J Immunol 1998;160:2998-3005.
43. de Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank WW, Nijkamp FP, Van Oosterhout AJ: Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy 2002;32:1651-1658.
44. Fujita T, Matsumoto Y, Hirai I, Ezoe K, Saito T, Yagihashi A, Torigoe T, Homma K, Takahashi S, Cruikshank WW, Jimbow K, Sato N: Immunosuppressive effect on T cell activation by interleukin-16-cDNA-transfected human squamous cell line. Cell Immunol 2000;202:54-60.
45. Bastien Y, Todedano BJ, Mehio N, Cameron L, Lamoukhaid B, Renzi P, Hamid Q, Mazer BD: Detection of functional platelet-activating factor receptors on human tonsillar B lymphocytes. J Immunol 1999;162:5498-5505.
46. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P, Labeta MO: Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000;164:3480-3486.
47. Hermann E, Darcissac E, Idziorek T, Capron A, Bahr GM: Recombinant interleukin-16 selectively modulates surface receptor expression and cytokine release in macrophages and dendritic cells. Immunology 1999;97:241-248.
48. Mathy NL, Scheuer W, Lanzendorfer M, Honold K, Ambrosius D, Norley S, Kurth R: Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 2000;100:63-69.